ag 112 has been researched along with tyrphostin a23 in 3 studies
| Studies (ag 112) | Trials (ag 112) | Recent Studies (post-2010) (ag 112) | Studies (tyrphostin a23) | Trials (tyrphostin a23) | Recent Studies (post-2010) (tyrphostin a23) |
|---|---|---|---|---|---|
| 19 | 0 | 10 | 160 | 0 | 28 |
| Protein | Taxonomy | ag 112 (IC50) | tyrphostin a23 (IC50) |
|---|---|---|---|
| alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein | Homo sapiens (human) | 9.97 | |
| intestinal alkaline phosphatase precursor | Mus musculus (house mouse) | 4.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gazit, A; Gilon, C; Levitzki, A; Yaish, P | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
3 other study(ies) available for ag 112 and tyrphostin a23
| Article | Year |
|---|---|
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.
Topics: Benzylidene Compounds; Carcinoma, Squamous Cell; Cell Division; Cell Line; Epidermal Growth Factor; ErbB Receptors; Humans; Kinetics; Molecular Structure; Nitriles; Phosphorylation; Protein-Tyrosine Kinases; Structure-Activity Relationship | 1989 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |